BiotechTube

Palifermin

Phase 1/2Terminated
0 views this week 0 watching💤 Quiet
Interest: 24/100
24
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Toxic Epidermal Necrolysis

Conditions

Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome

Trial Timeline

Oct 1, 2010 → Dec 1, 2014

NCT ID
NCT02037347

About Palifermin

Palifermin is a phase 1/2 stage product being developed by Swedish Orphan Biovitrum for Toxic Epidermal Necrolysis. The current trial status is terminated. This product is registered under clinical trial identifier NCT02037347. Target conditions include Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome.

What happened to similar drugs?

0 of 1 similar drugs in Toxic Epidermal Necrolysis were approved

Approved (0) Terminated (0) Active (1)
🔄Butenafine HCl 1% (BAY1896425)BayerPhase 3

Hype Score Breakdown

Clinical
9
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02037347Phase 1/2Terminated

Competing Products

13 competing products in Toxic Epidermal Necrolysis

See all competitors
ProductCompanyStageHype Score
TURALIO™Daiichi SankyoPre-clinical
33
Amifostine + Carboplatin + PaclitaxelAstraZenecaPhase 2
35
SaquinavirRochePhase 2
35
Doxycycline 50Mg TabletAmgenPhase 2
35
HPN-100 + HPN-100 or Placebo + Placebo + Moxifloxacin + HPN-100 + HPN-100AmgenPhase 1
29
Nivolumab & Tumor Infiltrating Lymphocytes with/without Interferon-AlphaBristol Myers SquibbPhase 1/2
28
Seasonal influenza vaccine - VAXIGRIP TETRA influenza vaccine (quadrivalent, split virion, inactivated)SanofiPre-clinical
26
Butenafine HCl 1% (BAY1896425)BayerPhase 3
37
ClinOleic (Baxter Healthcare, Deerfield, IL, USA)BaxterPhase 1
22
SENS-401 (R-Azasetron Besylate)SensorionPhase 2
25
TNX-1300Tonix PharmaceuticalsPhase 2
17
ADX-629 + PlaceboAldeyra TherapeuticsPhase 1/2
22
Ryanodex (dantrolene sodium) for injectable suspensionEagle PharmaceuticalsPhase 2
17